WHO Prioritizes Three Experimental Treatments for Bundibugyo Ebola Strain

Key Takeaways

• WHO flags MBP134, maftivimab, remdesivir as priority therapies
• No licensed vaccine or treatment exists for Bundibugyo Ebola strain
• Regeneron's maftivimab already stocked in DRC for rapid use
• Combination of monoclonal antibody and remdesivir under evaluation
• ChAdOx1 Bundibugyo vaccine could enter trials within months

Pulse Analysis

The Bundibugyo strain of Ebola, first identified in 2007, has resurfaced with a cluster of cases in the Democratic Republic of the Congo and neighboring Uganda. Unlike the more familiar Zaire strain, Bundibugyo lacks any approved therapeutic or prophylactic options, leaving health systems vulnerable. WHO’s rapid identification of three experimental treatments reflects a broader shift toward pre‑emptive drug evaluation during outbreaks, a strategy that aims to shorten the lag between emergence and effective clinical response.

Among the highlighted candidates, Mapp Biopharmaceutical’s MBP134, a monoclonal‑antibody cocktail, and Regeneron’s maftivimab, already pre‑positioned in the DRC, offer the most immediate deployment potential. Gilead’s remdesivir, an antiviral with a proven safety profile in other viral infections, is being considered both as a standalone therapy and in combination with maftivimab to enhance efficacy. The inclusion of an oral post‑exposure prophylaxis, obeldesivir, underscores WHO’s emphasis on layered interventions that can be tailored to exposure risk, provided contact‑tracing capacities are strengthened.

Vaccine development remains a longer‑term focus. The ChAdOx1 Bundibugyo candidate, leveraging the Oxford‑Serum Institute platform, could move to human trials within a few months, while the rVSV Bundibugyo vaccine may require up to nine months before trial readiness. Existing Ebola vaccine Ervebo was deemed unsuitable for Bundibugyo without further data. By mandating rigorously designed trials and partnering with African CDC and local health ministries, WHO aims to generate actionable evidence that could not only contain the current outbreak but also establish a template for rapid therapeutic assessment in future zoonotic emergencies.